Table 1 Demographic and clinical characteristics of the study participants by time of assessment
Therapy period | |||||||||
|---|---|---|---|---|---|---|---|---|---|
Before therapy (T0) | 1 month after therapy (T1) | ≧3 months after therapy (T2) | Total | ||||||
(n = 135)a | (n = 117)b | (n = 381)c | (n = 633)d | ||||||
N | % | N | % | N | % | N | % | ||
Age | Mean ± SD | 70.0 ± 7.6 | 70.4 ± 7.6 | 70.9 ± 7.1 | 70.6 ± 7.3 | ||||
Median (Range) | 70.1 (48.8-90.8) | 70.7 (48.8-92) | 70.2 (49-93) | 70.2 (48.8-93) | |||||
Treatment | Surgery | 57 | 42.2 | 48 | 41.0 | 162 | 42.6 | 267 | 42.2 |
Irradiation | 38 | 28.1 | 35 | 29.9 | 156 | 41.1 | 229 | 36.2 | |
Hormone therapy | 31 | 23.0 | 31 | 26.5 | 60 | 15.8 | 122 | 19.3 | |
Chemical therapy | 9 | 6.7 | 3 | 2.6 | 2 | 0.5 | 14 | 2.2 | |
PSA | Mean ± SD | 46.3 ± 126.9 | 10.9 ± 33.5 | 2.8 ± 16.6 | 12.8 ± 61.7 | ||||
PSA group | <=2.5 | 32 | 27.8 | 66 | 64.7 | 304 | 83.1 | 402 | 69.0 |
2.501-4 | 6 | 5.2 | 4 | 3.9 | 21 | 5.7 | 31 | 5.3 | |
4.001-6 | 9 | 7.8 | 8 | 7.8 | 14 | 3.8 | 31 | 5.3 | |
6.001-10 | 24 | 20.9 | 4 | 3.9 | 14 | 3.8 | 42 | 7.2 | |
>10 | 44 | 38.3 | 20 | 19.6 | 13 | 3.6 | 77 | 13.2 | |
Gleason score | 2-4 | 17 | 14.2 | 13 | 12.1 | 53 | 14.9 | 83 | 14.3 |
5-7 | 70 | 58.3 | 58 | 54.2 | 203 | 57.2 | 331 | 56.9 | |
> = 8 | 33 | 27.5 | 36 | 33.6 | 99 | 27.9 | 168 | 28.9 | |
Stage | I | 1 | 0.8 | 1 | 0.9 | 4 | 1.1 | 6 | 1.0 |
II | 84 | 67.2 | 75 | 67.0 | 276 | 75.8 | 435 | 72.4 | |
III | 20 | 16.0 | 21 | 18.8 | 57 | 15.7 | 98 | 16.3 | |
IV | 20 | 16.0 | 15 | 13.4 | 27 | 7.4 | 62 | 10.3 | |